Körfer A - Search Results

1

Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2.

Atzpodien J, Körfer A, Hadam M, Schomburg A, Menzel T, Dallmann I, Poliwoda H, Kirchner H. Atzpodien J, et al. Among authors: korfer a. Mol Biother. 1991 Jun;3(2):60-2. Mol Biother. 1991. PMID: 1910621

2

Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.

Duensing S, Hadam M, Körfer A, Schomburg A, Menzel T, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Duensing S, et al. Among authors: korfer a. Mol Biother. 1992 Dec;4(4):170-3. Mol Biother. 1992. PMID: 1282326

3

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.

Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: korfer a. Nat Immun. 1992 May-Jun;11(3):133-43. Nat Immun. 1992. PMID: 1392401

4

Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.

Schomburg A, Menzel T, Hadam M, Duensing S, Körfer A, Kirchner H, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: korfer a. Mol Biother. 1992 Jun;4(2):58-65. Mol Biother. 1992. PMID: 1515095

5

Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.

Freund M, Giller S, Hinrichs F, Baars A, Meran J, Körfer A, Link H, Poliwoda H. Freund M, et al. Among authors: korfer a. J Cancer Res Clin Oncol. 1991;117(5):489-92. doi: 10.1007/BF01612772. J Cancer Res Clin Oncol. 1991. PMID: 1890142 Clinical Trial.

6

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. Hänninen EL, et al. Among authors: korfer a. Cancer Res. 1991 Dec 1;51(23 Pt 1):6312-6. Cancer Res. 1991. PMID: 1933892

7

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.

Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H. Atzpodien J, et al. Among authors: korfer a. Lancet. 1990 Jun 23;335(8704):1509-12. doi: 10.1016/0140-6736(90)93039-r. Lancet. 1990. PMID: 1972442

8

The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2.

Kirchner H, Körfer A, Evers P, Szamel MM, Knüver-Hopf J, Mohr H, Franks CR, Pohl U, Resch K, Hadam M, et al. Kirchner H, et al. Among authors: korfer a. Cancer. 1991 Apr 1;67(7):1862-4. doi: 10.1002/1097-0142(19910401)67:7<1862::aid-cncr2820670708>3.0.co;2-r. Cancer. 1991. PMID: 2004299

9

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.

Kirchner H, Körfer A, Palmer PA, Evers P, De Riese W, Knüver-Hopf J, Hadam M, Goldman U, Franks CR, Poliwoda H, et al. Kirchner H, et al. Among authors: korfer a. Mol Biother. 1990 Sep;2(3):145-54. Mol Biother. 1990. PMID: 2222898

10

Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.

Atzpodien J, Körfer A, Palmer PA, Franks CR, Poliwoda H, Kirchner H. Atzpodien J, et al. Among authors: korfer a. Ann Oncol. 1990 Sep;1(5):377-8. doi: 10.1093/oxfordjournals.annonc.a057779. Ann Oncol. 1990. PMID: 2261378 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters